financetom
Business
financetom
/
Business
/
Zoomd Technologies Q2 revenue up 40% 
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Zoomd Technologies Q2 revenue up 40% 
Aug 14, 2025 5:57 AM

Overview

* Zoomd ( ZMDTF ) Q2 revenue grows 40% YoY to $19.6 mln

* Adjusted EBITDA rises over 80%, reflecting improved operating margins

* Net income reaches $6.1 mln, marking ninth consecutive quarter of growth

Outlook

* Company focuses on expanding into new geographies and market segments

* Zoomd ( ZMDTF ) emphasizes AI-powered automation to boost operational efficiency

* Company partners with large agencies for user acquisition in core verticals

* Zoomd ( ZMDTF ) targets high-growth sectors for future expansion

Result Drivers

* GEOGRAPHIC EXPANSION - Increased presence in North America and Europe contributed to revenue growth

* SECTOR PENETRATION - Greater penetration in entertainment and E-commerce sectors drove revenue increase

* PLATFORM INTEGRATION - Integration with new media sources expanded platform reach, boosting revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $19.60

Revenue mln

Q2 $5.60

Adjusted mln

EBITDA

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biogen and Sage to scrap neurological disorder drug development after trial failure
Biogen and Sage to scrap neurological disorder drug development after trial failure
Jul 24, 2024
July 24 (Reuters) - Biogen and Sage Therapeutics ( SAGE ) do not plan to conduct further studies for their neurological disorder drug after it failed in a mid-stage trial, the drugmakers said on Wednesday. The experimental drug, SAGE-324, was being studied as a treatment for essential tremor, a disorder that causes uncontrollable shaking of the hands, arms and other...
Tesla Second-Quarter Earnings Miss Estimates Amid Lower Prices
Tesla Second-Quarter Earnings Miss Estimates Amid Lower Prices
Jul 24, 2024
06:46 AM EDT, 07/24/2024 (MT Newswires) -- Tesla (TSLA) shares dropped early Wednesday as the electric vehicle manufacturer's second-quarter earnings fell short of market expectations, impacted by lower vehicle prices and restructuring charges. Adjusted earnings declined to $0.52 per share for the June quarter from $0.91 the year before, the company said late Tuesday, trailing the Capital IQ-polled consensus of...
ING Previews Wednesday's Bank of Canada Policy Decision
ING Previews Wednesday's Bank of Canada Policy Decision
Jul 24, 2024
06:49 AM EDT, 07/24/2024 (MT Newswires) -- ING expects the Bank of Canada (BoC) to cut the policy rate by 25bps Wednesday at 9:45 a.m. ET. This is almost entirely priced in by financial markets (21bps), which currently expect 65bps of easing by year-end, wrote the bank in a note to clients. Consensus isn't unanimous, but the majority of economists...
Otis Worldwide Q2 Earnings Rise, Net Sales Fall; Updates 2024 Outlook
Otis Worldwide Q2 Earnings Rise, Net Sales Fall; Updates 2024 Outlook
Jul 24, 2024
06:50 AM EDT, 07/24/2024 (MT Newswires) -- Otis Worldwide ( OTIS ) reported Q2 adjusted non-GAAP earnings Wednesday of $1.06, up from $0.92 a year earlier. Analysts polled by Capital IQ expected $1.03. Net sales for the quarter ended June 30 was $3.60 billion, down from $3.72 billion a year earlier. Analysts surveyed by Capital IQ expected $3.73 billion. Otis...
Copyright 2023-2026 - www.financetom.com All Rights Reserved